Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda M Catanzaro

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|May 4, 2005
Data from clinical trialsLinda M Catanzaro, Gene D Morse
The Annals of Pharmacotherapy|January 25, 2014
Macitentan for the treatment of pulmonary arterial hypertensionIrene S Hong, Holly V Coe, Linda M Catanzaro
The Lancet. Infectious Diseases|March 24, 2006
Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapyGene D Morse, Linda M Catanzaro, Edward P Acosta
Current HIV/AIDS Reports|August 11, 2005
Drug interactions with antiretroviralsLinda M Catanzaro, Judianne C Slish, Robert DiCenzo, et al.
Journal of Pharmacy Practice|April 29, 2022
An Examination of Student Pharmacists' Perceptions Toward ImmunizationMichael Danilov, Kira Voyer, Linda M Catanzaro, et al.
Current Research in Pharmacology and Drug Discovery|December 15, 2021
Pharmacokinetic drug interactions of integrase strand transfer inhibitorsChi-Hua Lu, Edward M Bednarczyk, Linda M Catanzaro, et al.
Clinical Pharmacokinetics|March 1, 2008
Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairmentSarah M McCabe, Qing Ma, Judianne C Slish, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitorsQing Ma, Olanrewaju O Okusanya, Patrick F Smith, et al.
The American Journal on Addictions|December 7, 2007
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavirNiamh Higgins, Barry S Zingman, Judianne Slish, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Acquired Immune Deficiency Syndromes (1999)|May 4, 2005
Data from clinical trialsLinda M Catanzaro, Gene D Morse
The Annals of Pharmacotherapy|January 25, 2014
Macitentan for the treatment of pulmonary arterial hypertensionIrene S Hong, Holly V Coe, Linda M Catanzaro
The Lancet. Infectious Diseases|March 24, 2006
Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapyGene D Morse, Linda M Catanzaro, Edward P Acosta
Current HIV/AIDS Reports|August 11, 2005
Drug interactions with antiretroviralsLinda M Catanzaro, Judianne C Slish, Robert DiCenzo, et al.
Journal of Pharmacy Practice|April 29, 2022
An Examination of Student Pharmacists' Perceptions Toward ImmunizationMichael Danilov, Kira Voyer, Linda M Catanzaro, et al.
Current Research in Pharmacology and Drug Discovery|December 15, 2021
Pharmacokinetic drug interactions of integrase strand transfer inhibitorsChi-Hua Lu, Edward M Bednarczyk, Linda M Catanzaro, et al.
Clinical Pharmacokinetics|March 1, 2008
Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairmentSarah M McCabe, Qing Ma, Judianne C Slish, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitorsQing Ma, Olanrewaju O Okusanya, Patrick F Smith, et al.
The American Journal on Addictions|December 7, 2007
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavirNiamh Higgins, Barry S Zingman, Judianne Slish, et al.
Pageof 1